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Fatih Incekara1,2, Stephan Koene2, Arnaud J.P.E. Vincent1, Martin J. van den Bent3, Marion Smits2-BACKGROUND: Gross total resection (GTR) of the contrast enhancing (CE)
area will improve the survival of patients with glioblastoma (GBM). However,
GBM can infiltrate into the brain parenchyma, beyond the CE margins. It remains
unclear whether resection beyond the CE area (supratotal resection [SPTR]) can
improve survival without causing additional neurological deficits. The aim of the
present meta-analysis was to study the association between SPTR and overall
survival of patients of GBM.
-METHODS: Embase, PubMed, and other literature databases were searched
for eligible studies until August 2018. Studies involving patients with GBM that
had compared SPTR with GTR were included in the present study. The main
outcome was overall survival, presented as hazard ratios (HRs) with 95% con-
fidence intervals (CIs) and median overall survival differences with the 95% CIs.
-RESULTS: The meta-analysis, which included 6 studies and 1168 unique pa-
tients with GBM, showed that compared with GTR, SPTR of GBM resulted in a
53% lower risk of mortality at any time during follow-up (HR, 0.47; 95% CI, 0.31e
0.72; P[ 0.0005). The median overall survival of the SPTR group was 6.4 months
(95% CI, 3.2e9.7) longer than the GTR group (P [ 0.0001). Reports on post-
operative deficits were limited, and the quality of evidence was moderate to
very low.
-CONCLUSIONS: Compared with GTR, SPTR of GBM resulted in a lower risk of
mortality and longer median overall survival. However, the quality of evidence of
the available studies was poor. Therefore, it remains unclear whether SPTR is
safe and actually improves the survival of patients with GBM. Future prospective
trials and a standardized definition of SPTR are needed.
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Patients with glioblastoma (GBM) have a
poor prognosis with a median overall
survival of 15 months, despite safe and
maximal surgical resection, followed by
chemotherapy and/or radiotherapy.1 GBM
will typically appear on contrast-
enhanced magnetic resonance imaging
(MRI) studies as a contrast enhancing (CE)
tumor with central necrosis. Maximal and
safe surgical resection or gross total
resection (GTR) of the CE area is currently
the main goal of GBM surgery. Both the
rights reserved.WORLD NEUROSURGERY 127: 617-624,survival beneﬁts of GTR and the optimal
method to achieve this have been exten-
sively debated in neurosurgical studies.
Brown et al.1 showed, in a systematic
review and meta-analysis of 37 studies
and 41,117 unique patients, that compared
with subtotal resection, GTR of the CE
area will decrease the risk of mortality,
with 28% at 1 year and 16% at 2 years (P <
0.001). Jenkinson et al.2 recently showed
in a Cochrane review that resection with
5-aminolevulinic acid (5-ALA) ﬂuores-
cence guidance or intraoperative MRI
guidance can increase the extent of GBM
resection.
However, GBM is known to inﬁltrate far
beyond the CEmargins as seen onMRI into
the surrounding edematous T2-weightedJULY 2019 www.journals.elﬂuid-attenuated inversion recovery
(FLAIR) hyperintense region.3 This raises
the question of whether GTR of the CE
portion will constitute “total” resection or
whether surgical resection should also
include a part of the hyperintense T2-
weighted FLAIR region to improve sur-
vival. It has been suggested that 5-ALA
ﬂuorescence accumulates in cancer cells
and not only corresponds to the CE portion
on MRI but also exceeds this area as vague
ﬂuorescence, which corresponds with the
portions of GBM often inﬁltrating into an
eloquent brain area.4
This concept of so-called supramarginal
or supratotal resection (SPTR), is already
known in the ﬁeld of low-grade glioma
surgery,5,6 because low-grade gliomassevier.com/world-neurosurgery 617
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
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lack the CE target for surgical resection.
However, SPTR of GBM has been less
extensively investigated, and, to the best of
our knowledge, no quantitative data anal-
ysis has been performed to clarify the as-
sociation of survival with SPTR versus GTR
for patients with GBM and the post-
operative neurological complications.
The aim of the present study was to
investigate the association between SPTR
and survival in patients with GBM using a
systematic review and meta-analysis in
accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.7618 www.SCIENCEDIRECT.comMETHODS
Systematic Review
We searched for studies that had included
patients with GBM who had undergone
surgical resection and had pre- and post-
operative MRI studies available. Letters,
editorials, abstracts, and non-English ci-
tations were excluded. The search query
was designed with an expert librarian at
the Erasmus University Medical Center,
Medical Library, to capture all citations
reported until August 2018 within PubMed
[(Glioblastoma/ OR (glioblastom* OR
(maligna* ADJ3 glioma*) OR (high* ADJ3
grade* ADJ3 glioma*) OR ((grade-iv ORWORLD NEUROSURGERY, httpgrade-4) ADJ3 glioma*) OR gbm).ab,-
ti,kw.) AND (Surgical Procedures, Opera-
tive/ OR exp Neurosurgery/ OR
Neurosurgical Procedures/ OR exp Brain
Neoplasms/su OR (surg* OR neurosurg*
OR resect*).ab,ti,kw.) AND (Margins of
Excision/ OR (ﬂair OR (Fluid ADJ3
attenuat* ADJ3 invers* ADJ3 recover*) OR
t2 OR t-2 OR gross-total OR ((exten* OR
Supratotal* OR Supramaxim*) ADJ3
(resect* OR remov*)) OR ((surg* OR
excis* OR resect*) ADJ3 margin*) OR
((beyond OR additional*) ADJ6 (contrast
OR boundar*))).ab,ti,kw.) NOT (letter*
OR news OR comment* OR editorial* OR
congres* OR abstract* OR book* ORs://doi.org/10.1016/j.wneu.2019.04.092
Table 1. Study Demographics
Investigator Country Definition of GTR Definition of SPTR
HR Quality of Evidence (GRADE)z
Group
Comparison*
Multivariate
Analysisy
Aldave et al.,12 2013 Spain 100% of CE area 100% of CE þ total resection
of fluorescing tumor
Yes Yes 3
Li et al.,8 2016 USA 100% of CE area 100% of CE þ >0%e100% FLAIR Yes Yes 2
Eyüpoglu et al.,19 2016 Germany 100% of CE area 100% of CE þ total resection
of fluorescing tumor
Yes No 3
Pessina et al.,28 2017 Italy 100% of CE area 100% of CE þ 100% of FLAIR Yes Yes 3
Esquenazi et al.,18 2017 USA 95%e100% of CE area >100% of CE Yes Yes 3
Glenn et al.,21 2018 USA 100% of CE area 100% of CE þ >1 cm of
surrounding brain tissue
Yes Yes 4
GTR, gross total resection; SPTR, supratotal resection; HR, hazard ratio; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; CE, contrast enhancing; FLAIR, fluid-
attenuated inversion recovery.
*“Yes” indicates the HR should be interpreted as a between group comparison; “no” indicates the HR should be interpreted as per unit of residual T2-weighted FLAIR volume.
yIncluded prognostic factors in the model such as age, tumor volume, tumor location, Karnofsky performance scale, methylguanine-DNA methyltransferase methylation status, and adjuvant
therapy (Supplemental Table 2).
zQuality of evidence levels: 1, high; 2, moderate; 3, low; 4, very low (Supplemental Table 1).
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Embase, Web of Science, Cochrane Cen-
tral, and Google Scholar (search queries
for these sources are listed in the
Supplemental Materials).
After removing duplicate reports, 2 in-
dependent reviewers (F.I. and S.K.)
screened the studies by title and abstract
and removed off-topic citations. The full
text of the remaining reports were inde-
pendently read by the reviewers (F.I., S.K.)
to determine whether they were eligible
for ﬁnal inclusion. Studies of solely pedi-
atric or non-GBM cases, recurrent GBM,
nonoperative or surgery of the enhancing
tumor portion alone, or biopsy only and
studies without survival data were
excluded. The present study was per-
formed and presented in accordance with
the PRISMA guidelines.7
Data Collection
The main outcome of interest was overall
survival, presented as hazard ratios (HRs)
with 95% conﬁdence intervals (CIs), and
median overall survival with 95% CIs of the
GTR and SPTR groups. These data were
collected from the included studies, calcu-
lated from other available data, or extracted
based on data points created using a pixel-
by-pixel method from the survival curves.
GTR and SPTR were deﬁned by the authorsWORLD NEUROSURGERY 127: 617-624,of the studies included in our meta-analysis.
We categorized GTR as 100% resection of
the CE area, and SPTR as every effort to
resect beyondGTR of the CE portion, which
had been qualitatively or quantitatively
deﬁned by the authors of the included
studies. Li et al.8 presented their data on
survival and neurological outcomes mainly
by categorizing the resection as <53%
FLAIR and 53% FLAIR. However, after e-
mail correspondence with the senior
author, we received additional survival data
on the GTR and SPTR groups to perform
our meta-analysis.8 When available, data
on postoperative new neurological deﬁcits,
surgical complications, and/or quality of
life after surgery were collected to assess
the safety of both SPTR and GTR.
Meta-Analysis
The HRs with 95% CIs and median overall
survival with 95% CIs for the SPTR and
GTR groups were collected or calculated
for each study using the available data and
the random effects model and presented
in forest plots using Review Manager
(RevMan, version 5.3 [Cochrane Collabo-
ration, London, United Kingdom]). The
random effects model was used instead of
the ﬁxed effects model because of the
heterogeneity among the studies to pro-
vide a more conservative and clinicallyJULY 2019 www.journals.elreliable interpretation of the summarized
statistics and 95% CIs. The HRs had been
corrected by the authors of the individual
studies for several prognostic factors
across the studies such as age, Karnofsky
performance scale (KPS), adjuvant ther-
apy, tumor volume and location, and
methylguanine-DNA methyltransferase
(MGMT) methylation and isocitrate dehy-
drogenase (IDH) mutation status. A P
value of < 0.05 was considered to indicate
statistical signiﬁcance. Heterogeneity was
calculated and interpreted using the c2
test and I2 values with Review Manager
(Cochrane Collaboration).
Quality of Evidence
The quality of evidence obtained from the
reports included in the present study was
graded using the Grades of Recommenda-
tion, Assessment, Development, and Eval-
uation (GRADE) system9 (Supplemental
Table 1). Within the GRADE system, 4
levels of quality rating can be assigned to
studies: high, often given to randomized
controlled trials; moderate or low, often
given to observational studies; and very
low. The quality of evidence was rated by
1 of us (F.I.) and was determined from the
methodological quality, risk of biases
(using the ROBINS-I [risk of bias in non-
randomized studieseof interventions]sevier.com/world-neurosurgery 619
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effect estimates.RESULTS
We identiﬁed 1796 citations from Embase,
1503 from PubMed, 1424 from Web of
Science, 140 from Cochrane Central, and
200 from Google Scholar. Removal of the
duplicate reports resulted in 2346 unique
citations that were screened by title and
abstract. A total of 2322 off-topic studies
were excluded, leaving 24 that were read
in full.6,8,11-32 After reading, 18 reports
were excluded owing to the absence of
SPTR (n ¼ 11), absence of sufﬁcient sur-
vival data (n ¼ 4), and article type (n ¼ 3; 2
commentaries and 1 review). This resulted
in a ﬁnal total of 6 studies8,12,18,19,21,28 that
were included in our systematic review
and meta-analysis. The process of study
inclusion is presented in the PRISMA ﬂow
diagram in Figure 1, and demographics of
the included studies are presented in
Table 1.
Meta-Analysis
Our meta-analysis included 6 studies
comparing SPTR and GTR,8,12,18,19,21,28
with 1168 unique patients with GBM. Our
meta-analysis resulted showed that
compared with GTR, SPTR of GBM
resulted in a 53% lower risk of mortality at
any time during the follow-up period (HR,
0.47; 95% CI, 0.31e0.72; P ¼ 0.0005; I2,
68%; Figure 2).
The median overall survival for the GTR
and SPTR groups was 15.0 months (95% CI,
2.9e26.1) and 28.3 months (95% CI, 12.5eFigure 2. Forest plot with hazard ratios and 95
620 www.SCIENCEDIRECT.com44.1), respectively (P < 0.0001). The survival
beneﬁt with SPTR was 13.3 months (95% CI,
3.6e23.1) compared with GTR (P ¼ 0.007).
However, the ﬁndings from Esquenazi
et al.,18 in particular, inﬂuenced the
heterogeneity (I2) of the median overall
survival analysis, possibly owing to the
much greater median overall survival for
the SPTR group of 54 months within their
study. The exclusion of their study in an
additional median overall survival analysis
showed a decrease of I2 from 96% to 50%.
Compared with GTR, SPTR of GBM
resulted in a longer median overall
survival of 6.4 months (95% CI, 3.2e9.7;
P ¼ 0.0001; Figure 3).
Quality of Evidence
No randomized controlled trials were avail-
able for inclusion in the present meta-
analysis. All the studies were retrospective
with a nonrandomized treatment assign-
ment. Using the GRADE guidelines, the
studieswere assigned to the low-level12,18,19,28
quality evidence and then possibly upgraded
to a moderate level8 or downgraded to a very
low level21 (Table 1) using previously stated
mainly methodological factors such as study
design, internal validity, risk of biases, and
precision (Supplemental Table 1).
Postoperative New Neurological Deficits
In 3 studies, the incidence rates of post-
operative new neurological deﬁcits for both
SPTR (range, 0%e19%) and GTR (range,
0%e8%) groups were reported. However, in
the other 3 studies, these data either were not
clearly presented or were absent (Table 2).% confidence intervals (CIs) for supratotal resection (SP
WORLD NEUROSURGERY, httpOverall, the reports were limited; thus, the
difference in postoperative neurological
outcomes between SPTR versus GTR could
not clearly be analyzed.DISCUSSION
The present PRISMA guided systematic
review and meta-analysis studied the as-
sociation between SPTR and survival in
patients with GBM. Our analysis included
6 studies and 1168 unique patients and
showed that compared with GTR, SPTR of
GBM resulted in a 53% lower risk of
mortality at any time during the follow-up
period and a 6.4-month longer median
overall survival duration. The quality of
evidence for the available studies, howev-
er, was moderate to very low. Further-
more, the incidence rates of postoperative
new neurological deﬁcits was minimally
and only qualitatively reported. Finally,
data on the patients’ quality of life were
not reported in any of the included
studies. It, therefore, remains unclear
whether SPTR can be achieved as safely as
GTR.
Defining SPTR
A multitude of deﬁnitions have been used
for SPTR. The term was ﬁrst used by
Yordanova and Duffau33 in 2011 to explain
the procedure of low-grade glioma resec-
tion guided by functional boundaries,
deﬁned by the area of T2-weighted FLAIR
hyperintensity during awake surgery,
instead of the classic neuronavigation us-
ing preoperative MRI contrast-enhanced
scans. Yordanova and Duffau33 showedTR) versus gross total resection (GTR).
s://doi.org/10.1016/j.wneu.2019.04.092
Figure 3. Forest plot with median overall survival differences between supratotal resection (SPTR) and gross total resection (GTR). CI, confidence interval.
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a signiﬁcant delay of anaplastic degener-
ation (P ¼ 0.037) without causing perma-
nent neurological deﬁcits.
With SPTR of GBM, the classically used
CEboundaries of the tumorwill be exceeded
to include the nonenhancing hyperintense
T2-weighted FLAIR region during resection,
presumed to represent edematous, tumor-
inﬁltrated tissue. This region can inﬁltrate
deep into eloquent brain areas.3 For our
analysis, we considered any effort of
resection beyond GTR of the CE areas as
SPTR, irrespective of the procedure used to
achieve the resection. Some studies used a
relatively conservative SPTR procedure
such as resection of additional residual 5-
ALAeﬂuorescent tissue12,19 or resection of
an additional rim (>1 cm) after GTR of the
CE area.21 However, Li et al.8 and Pessina
et al.28 deﬁned SPTR as additionalTable 2. Reported Incidence Rates of Postop
Investigator GTR
Aldave et al.,12 2013 2 (8)
Li et al.,8 2016 NA
Glenn et al.,21 2018 0 (0)
Pessina et al.,28 2017 0 (0)
Eyüpoglu et al.,19 2016 NA
Esquenazi et al.,18 2017 NA
GTR, gross total resection; SPTR, supratotal resection; NA, not
WORLD NEUROSURGERY 127: 617-624,resection of FLAIR abnormalities (range,
>0%e100%) and 100% resection of T2-
weighted FLAIR hyperintense volumes in
addition to GTR of the CE areas, respec-
tively. Additionally, a very recent study
deﬁned SPTR as GTR plus frontal or tem-
poral lobectomy, without any volumetric
analysis on the T2-weighted FLAIR volumes
or functionally deﬁned borders during
awake surgery.34 Therefore, based on the
reported data, SPTR can only broadly be
deﬁned as every effort of resection after
GTR of the CE portion of GBM. No
standardized deﬁnition of SPTR exists;
thus, SPTR needs to be deﬁned in a
prospective setting.
Li et al.8 highlighted that compared with
GTR the relatively low rates of postoperative
new neurological deﬁcits in the SPTR group
could probably be explained by the
increased use of awake surgery witherative Neurological Deficits
SPTR P Value
4 (18.5) 0.27
120 (19) NA Motor d
most co
1 (11.1) 0,66
0 (0) NA No p
NA 0.47e1.0 Rates o
grou
worsen
NA NA Of 38
perma
applicable.
JULY 2019 www.journals.elneurophysiological monitoring, cortical
and/or subcortical mapping, and imaging
guidance such as intraoperative MRI,
functional MRI, and diffusion tensor
imaging navigation.2,8 Although Jenkinson
et al.2 showed in a recent Cochrane review
that intraoperative MRI or 5-ALA
ﬂuorescent-guided surgery can help to in-
crease the extent of GBM resection, the re-
ports on adverse events were incomplete and
the studies had very low quality evidence.
Because portions of the hyperintense T2-
weighted FLAIR area could represent both
tumor-inﬁltrated edematous and solely
edematous portions, additional methods to
delineate non-CE tumor inﬁltration are
important to obtain a target for SPTR.
Resection of the former might contribute to
better patient survival, although the impact of
the latter on survival will be limited, but could
also pose an unnecessary risk ofComment
No details on deficits reported
eficits and speech and visual impairments were the
mmonly reported 30-day postoperative neurological
complications
One patient with dysphasia
atient developed postoperative new neurological
deficits in either group
n postoperative new neurological deficits between
ps not clearly collectable; overall, no significant
ing of motor, visual, speech, or cognitive deficits or
seizures reported in either group
patients, 3 (7.9%) had transient and 2 (5.3%) had
nent neurological deficits; group-specific data not
reported
sevier.com/world-neurosurgery 621
LITERATURE REVIEW
FATIH INCEKARA ET AL. SPTR OF GBM: SYSTEMATIC REVIEW AND META-ANALYSIScomplications. In addition to 5-ALA, physi-
ological preoperative MRI such as positron
emission tomography MRI might help to
identify tumor-inﬁltrated, highly metabolic
portions outside the CE areas of GBM as a
speciﬁc target during surgery.35
Study Limitations
Overall, the results of our analysis should
be interpreted with caution because of
several limitations. First, the between-
study heterogeneity (I2 ¼ 68%) across the
analyzed studies, which possibly arose
from several factors, included the differ-
ences in deﬁning SPTR, the heteroge-
neous or limited sizes of the small study
populations across the studies, and their
retrospective design and nonrandomized
treatment assignment. As stated previ-
ously, the different deﬁnitions of SPTR
across the studies, which were often
retrospectively deﬁned and varied between
additional resection of ﬂuorescing tumor
tissue to total resection of T2-weighted
FLAIR hyperintensity in addition to GTR
of the CE area, made it challenging to
draw clear conclusions that would beneﬁt
the clinical practice of neurosurgeons.
Second, because the survival beneﬁt and
safety of resecting T2-weighted FLAIR
hyperintense regions remains unclear, no
clinical equipoise was found to randomize
patients with GBM into SPTR or GTR
groups. Therefore, SPTR was probably
performed for only a selected group of
patients, because extending the limits of
GBM resection beyond the CE area was
often not the main goal of the surgery,
especially not for tumors located in
eloquent brain areas.
Finally, a heterogeneous patient popula-
tionwith different prognostic factors such as
age, KPS score, adjuvant therapy, IDH mu-
tation and MGMT methylation status, and
tumor volume and location were present
across the 6 studies (Supplemental Table 2).
Although corrections for some of these
factors were applied in the multivariate
analyses across the studies, the real effect
of these factors for achieving SPTR and
survival were difﬁcult to determine owing
to the retrospective nature of the studies.
GBM location and the nearness of the
tumor to eloquent areas is a known
important prognostic factor. A very recent
study suggested that GBMs located in
noneloquent areas such as the frontal or
temporal pole could possibly undergo safe622 www.SCIENCEDIRECT.comSPTR with total lobectomy.34 However, no
clear comparison with GBMs located in
eloquent areas was available. In the reports
we included in our study, only limited
correction for GBM eloquence was
performed (Supplemental Table 2).
Furthermore, some of these factors, such
as genetic mutations and location and
tumor size, are intercorrelated; thus, their
inﬂuence on survival would be difﬁcult to
investigate retrospectively. Patients with
GBM with an IDH mutation (and MGMT
methylation) will have signiﬁcantly better
survival, although, at the same time, these
tumors have more often been located in
the frontal pole and have had a larger size.36
These limitations introduced biases
such as confounding by indication, avail-
able information, and selection biases in
the analyzed studies, which, consequently,
negatively inﬂuenced the internal validity
and quality of the studies. Because the
quality of evidence of the analyzed studies
were only moderate to very low, the
beneﬁt of SPTR of GBM on survival and its
safety remains unclear and, thus, should
not yet be considered as a main goal of
GBM surgery.
With consideration of these limitations,
we used a random effects model to pro-
vide a conservative, but clinically more
reliable and meaningful, interpretation of
the treatment effect of SPTR.37 The
random effects model summary results of
a HR of 0.47 (95% CI, 0.31e0.72) and
median overall survival beneﬁt of 6.4
months (95% CI, 3.2%e9.7%) provides a
more reliable average estimate effect
because it considers the real differences
in the SPTR versus GTR effect in each
study and provides greater uncertainty
around the estimate compared with the
ﬁxed effects model summary results of a
HR of 0.67 (95% CI, 0.58e0.78) and a
median overall survival beneﬁt of 4.6
months (95% CI, 3.9e6.0).
In addition, SPTR should not be
attempted at any cost. As always, the aim
of GBM surgery should be to maximize the
extent of GBM resection without causing
new neurological deﬁcits and maintaining
a good quality of life for patients. Any
potential beneﬁts of prolonged survival by
extending the tumor resection could be
considered by exploring the functional
boundaries during awake surgery and
additional imaging adjuncts such intra-
operative MRI, ultrasound, and 5-ALAWORLD NEUROSURGERY, httpguidance. This potential beneﬁt should
be weighed, together with the patient,
against the risk of extending the bound-
aries of GBM resection and its effect on
postoperative neurological functioning
and quality of life.
In our study, the incidence of post-
operative new neurological deﬁcits was not
well reported across the different studies.
Postoperative neurological status was re-
ported only descriptively, without the use of
validated tests and quantitative outcome
measures. Additionally, no data on patient
quality of life were reported across the
studies. The safety of the procedure,
therefore, could not be established.
Future Directions
Future, well-designed, prospective, ran-
domized controlled trials are needed to
investigate both the safety and the survival
beneﬁt of SPTR of GBM. These trials
should include prospective and clearly
deﬁned volumetric SPTR measures to
standardize the deﬁnition of SPTR. Such a
standardized deﬁnition of SPTR would be
expected to improve comparability be-
tween studies and improve the quality of
evidence of studies investigating SPTR of
GBM. Advanced physiological imaging
techniques could also be used to identify
noneCE-inﬁltrating, residual tumor
beyond the CE margins. Finally, validated
measures for postoperative neurological
outcomes and quality of life assessments
(i.e., European Organization for Research
and Treatment of Cancer core quality of
life questionnaire and/or brain cancer
module) that have been corrected for
important prognostic factors such as age,
KPS score, use of adjuvant therapy, and
IDH mutation and MGMT methylation
status should be used to study the beneﬁt
of SPTR of GBM on patient survival and
safety.38CONCLUSIONS
To the best of our knowledge, we have
performed the ﬁrst meta-analysis of SPTR
for GBM. Our results suggest that
compared with GTR, SPTR of GBM results
in a lower risk of mortality at any time
during the follow-up period and longer
overall median survival. These results
should, however, be interpreted with
caution, because the quality of the avail-
able evidence was only moderate to verys://doi.org/10.1016/j.wneu.2019.04.092
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reached on the deﬁnition of SPTR, and no
reliable information on the safety of SPTR
was available. Therefore, from the current
available data, the beneﬁt of SPTR of GBM
on survival and its safety remains unclear
and should not yet be considered as the
standard of care for GBM surgery. Our
ﬁndings, however, should encourage
further investigation in well-designed,
prospective, randomized trials to clarify
whether SPTR can be achieved safely to
improve the survival of patients with GBM.
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Search Queries for Several Literature
Sources
Embase.com. (’glioblastoma’/exp OR (glio-
blastom* OR (maligna* NEAR/3 glioma*)
OR (high*NEAR/3 grade*NEAR/3 glioma*)
OR ((grade-ivORgrade-4)NEAR/3 glioma*)
OR gbm):ab,ti,kw) AND (’surgery’/de OR
’neurosurgery’/exp OR ’cancer surgery’/exp
OR ’brain surgery’/exp OR ’brain tumor’/
exp/dm_su OR ’surgical technique’/de OR
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margin’/exp OR ’ﬂuid attenuated inversion
recovery’/de OR ’ﬂuid attenuated inversion
recovery imaging’/de OR ’gross total resec-
tion’/de OR (ﬂair OR (Fluid NEAR/3
attenuat* NEAR/3 invers* NEAR/3 recover*)
OR t2OR t-2 OR gross-total OR ((exten*ORSupplemental Table 1. Grades of Recommen
Investigator Quality Level*
Aldave et al.,12 2013 3 Non
Li et al.,8 2016 2 Non
Eyüpoglu et al.,19 2016 3 Non
Pessina et al.,28 2017 3 Non
Esquenazi et al.,18 2017 3 Non
Glenn et al.,21 2018 4 Non
CI, confidence interval.
*Quality of evidence levels (Grades of Recommendation, Asses
yROBINS-I (risk of bias in nonrandomized studies e of interventi
serious, and critical risks of bias or no information.
WORLD NEUROSURGERY 127: 617-624,Supratotal* OR Supramaxim*) NEAR/3
(resect* OR remov*)) OR ((surg* OR excis*
OR resect*) NEAR/3 margin*) OR ((beyond
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NEAR/3 attenuat* NEAR/3 invers* NEAR/3
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((exten* OR Supratotal* OR Supramaxim*)
NEAR/3 (resect* OR remov*)) OR ((surg*
OR excis* OR resect*) NEAR/3 margin*)
OR ((beyond OR additional*) NEAR/6
(contrast OR boundar*))):ab,ti,kw)dation, Assessment, Development, and Evaluati
Underlying Study Method Risk of B
random treatment allocation, retrospective Modera
random treatment allocation retrospective Modera
random treatment allocation retrospective Modera
random treatment allocation retrospective Modera
random treatment allocation retrospective Modera
random treatment allocation, retrospective Seriou
sment, Development, and Evaluation Quality): 1, high; 2, moderate
ons) tool, based on risks of selection, information, and confounding
JULY 2019 www.journals.elseviCochrane CENTRAL. ((glioblastom* OR
(maligna* NEAR/3 glioma*) OR (high*
NEAR/3 grade* NEAR/3 glioma*) OR
((grade-iv OR grade-4) NEAR/3 glioma*)
OR gbm):ab,ti,kw) AND ((surg* OR neu-
rosurg* OR resect*):ab,ti,kw) AND ((ﬂair
OR (Fluid NEAR/3 attenuat* NEAR/3
invers* NEAR/3 recover*) OR t2 OR "t 2"
OR "gross total" OR ((exten* OR Supra-
total* OR Supramaxim*) NEAR/3 (resect*
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resect*) NEAR/3 margin*) OR ((beyond
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glioma"j"high grade glioma" ﬂairj"Fluid
attenuating inverse"j"gross total"-
j"SupratotaljSupramaximal resec-
tion"j"extent of resection"on Quality Ranking
iasy Precision
te Low patient numbers; wide 95% CIs
te High patient numbers, narrow 95% CIs
te Moderate patient numbers and 95% CIs
te Moderate patient numbers and 95% CIs
te Low patient numbers, wide 95% CIs
s Low patient numbers, wide 95% CIs
; 3, low; 4, very low.
biases, with summarized judgments that include moderate,
er.com/world-neurosurgery 624.E1
Supplemental Table 2. Overview of Multivariate Analyses Across Studies with Adjustment for Prognostics Factors
Investigator Multivariate Analysis Prognostic Factors as Variables
Aldave et al.,12 2013 Yes Age, KPS score, MGMT methylation status, tumor eloquent location,
preoperative tumor volume, adjuvant therapy
Li et al.,8 2016 Yes Unclear, at least treatment history
Eyüpoglu et al.,19 2016 No Not performed
Pessina et al.,28 2017 Yes Age, extent of CE resection, tumor location
Esquenazi et al.,18 2017 Yes Age, tumor volume, KPS score, intraoperative mapping, BCNU wafer
Glenn et al.,21 2018 Yes MGMT methylation status, tumor laterality
KPS, Karnofsky performance scale; MGMT, methylguanine-DNA methyltransferase; CE, contrast enhancing; BCNU, bis-chloroethylnitrosourea (or carmustine).
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